Cargando…

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma

BACKGROUND: Melanoma is categorized as one of the most malignant, severe, and lethal cancers of the skin. Regarding the lack of efficiency of conventional therapies for most patients, novel therapeutic strategies are strongly required. OBJECTIVE: The current study aimed to assess the impact of AZD67...

Descripción completa

Detalles Bibliográficos
Autores principales:	Talebpoor, Maryam, Neshasteh-Riz, Ali, Koosha, Fereshteh, Eynali, Samira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shiraz University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175119/ https://www.ncbi.nlm.nih.gov/pubmed/35698544 http://dx.doi.org/10.31661/jbpe.v0i0.1912-1000

Ejemplares similares

The Use of ß-Elemene to Enhance Radio Sensitization of A375 Human Melanoma Cells
por: Balavandi, Zahra, et al.
Publicado: (2020)

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice
por: Kiesel, Brian F., et al.
Publicado: (2022)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage
por: Suzuki, Takuya, et al.
Publicado: (2022)

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
por: Vendetti, Frank P., et al.
Publicado: (2015)

The Combination of Metformin and Disulfiram-Cu for Effective Radiosensitization on Glioblastoma Cells
por: Rezaei, Narges, et al.
Publicado: (2020)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

DNA Damage Induced in Glioblastoma Cells by I-131: A Comparison between Experimental Data and Monte Carlo Simulation
por: Neshasteh-Riz, Ali, et al.
Publicado: (2012)

AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
por: Harata, Shinnosuke, et al.
Publicado: (2023)

Evaluation of the electromagnetic field intensity in operating rooms and estimation of occupational exposures of personnel
por: Ghazikhanlou-Sani, Karim, et al.
Publicado: (2018)

AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
por: Huang, Longxiang, et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
por: Dillon, M.T., et al.
Publicado: (2018)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

Evaluation of The Combined Effects of Hyperthermia, Cobalt-60 Gamma Rays and IUdR on Cultured Glioblastoma Spheroid Cells and Dosimetry Using TLD-100
por: Neshasteh-Riz, Ali, et al.
Publicado: (2014)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
por: Ring, Alistair, et al.
Publicado: (2023)

Evaluation of the Combined Effect of 2ME2 and (60)Co on the Inducement of DNA Damage by IUdR in a Spheroid Model of the U87MG Glioblastoma Cancer Cell Line Using Alkaline Comet Assay
por: Khoei, Samideh, et al.
Publicado: (2011)

Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.
por: Neshasteh-Riz, A., et al.
Publicado: (1997)

DNA Damage of Glioblastoma Multiform Cells Induced by Beta Radiation of Iodine-131 in The Presence or Absence of Topotecan: A Picogreen and Colonogenic Assay
por: Eyvazzadeh, Nazila, et al.
Publicado: (2015)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

Relative Biological Effectiveness (RBE) of (131)I Radiation Relative to (60)Co Gamma Rays
por: Neshasteh-Riz, Ali, et al.
Publicado: (2013)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
por: Davis, S. Lindsey, et al.
Publicado: (2022)

Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents
por: Frasinyuk, Mykhaylo, et al.
Publicado: (2022)

Genotoxic Damage to Glioblastoma Cells Treated with 6 MV X-Radiation in The Presence or Absence of Methoxy Estradiol, IUDR or Topotecan
por: Eyvazzadeh, Nazila, et al.
Publicado: (2015)

Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer
por: Chen, Shuo, et al.
Publicado: (2016)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
por: Wang, Luqi, et al.
Publicado: (2018)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
por: Zhu, Jian, et al.
Publicado: (2019)

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
por: Sule, Amrita, et al.
Publicado: (2021)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i85hjhfshqd50i5km4c1epmtrq